CH505 TF mRNA-gp160(National Institute Of Allergy And Infectious Diseases)
- Generic Name
- CH505 TF mRNA-gp160(National Institute Of Allergy And Infectious Diseases)
A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV
Phase 1
Recruiting
- Conditions
- HIV Infections
- Interventions
- Biological: CH505M5 N197D mRNA-gp160
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-01-29
- Target Recruit Count
- 48
- Registration Number
- NCT06557785
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center (Site ID: 32077), Boston, Massachusetts, United States
🇺🇸Columbia P&S (Site ID: 30329), New York, New York, United States
🇺🇸New York Blood Center (Site ID: 31801), New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath